Gildess Fe 1.5/30

Endometriosis, Low Testosterone, Osteoporosis + 16 more

Treatment

20 Active Studies for Gildess Fe 1.5/30

What is Gildess Fe 1.5/30

Norethisterone

The Generic name of this drug

Treatment Summary

Norethisterone (also known as norethindrone) is a synthetic hormone that is similar to the hormone progesterone. It is used to treat irregular menstruation and endometriosis, as well as in combination with other hormones for contraception and hormone replacement therapy. Norethisterone was first developed in 1951 and was approved for use as an oral contraceptive in 1962.

Necon

is the brand name

image of different drug pills on a surface

Gildess Fe 1.5/30 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Necon

Norethisterone

1967

347

Effectiveness

How Gildess Fe 1.5/30 Affects Patients

Norethisterone is a medication taken orally that is used for birth control or to treat hormone-related issues like menopause symptoms and endometriosis. It works in a similar way to the body's natural progesterone but with a higher potency. Norethisterone affects the reproductive organs and ovulation, as well as hormones in the brain related to fertility, but it also increases the risk of developing breast cancer. People taking this medication should be aware of this possibility and regularly check their breasts for any lumps or changes.

How Gildess Fe 1.5/30 works in the body

Norethisterone works by binding to receptors in cells in the reproductive tract, breast, pituitary, hypothalamus, skeletal tissue, and central nervous system. This binding leads to changes in the cervical mucus, endometrium, and hormones like FSH and LH. These changes make it difficult for sperm to enter the uterus, make the endometrium inhospitable for implantation, and prevent ovulation. When used in hormone replacement therapy for menopausal women, norethisterone works to suppress the growth of the endometrium. It also has a low affinity for androgen and glucocorticoid

When to interrupt dosage

The proposed dosage of Gildess Fe 1.5/30 is dependent upon the specified condition, such as Atrophic, Fracture and Hormone Replacement Therapy. The dose is contingent upon the method of administration (e.g. Oral or Tablet) featured in the table underneath.

Condition

Dosage

Administration

Fracture

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Atrophic

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

hypoestrogenism

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hot flashes

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Birth Control

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Therapeutic procedure

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Menopause

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Estrogen Deprivation Symptoms

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Oral Contraceptives

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Low Testosterone

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis, Postmenopausal

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Primary Ovarian Insufficiency

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormonal Contraception

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

female castration

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormone Replacement Therapy

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Vasomotor System

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Gildess Fe 1.5/30 has eight contraindications and should not be paired with the conditions shown in the table below.

Gildess Fe 1.5/30 Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thrombophilia

Do Not Combine

Vaginal Hemorrhage

Do Not Combine

Malignant Neoplasms

Do Not Combine

Benign hepatic neoplasm

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Norethisterone may interact with Pulse Frequency

There are 20 known major drug interactions with Gildess Fe 1.5/30.

Common Gildess Fe 1.5/30 Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Norethisterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Norethisterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.

Clomipramine

Major

The metabolism of Clomipramine can be increased when combined with Norethisterone.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Norethisterone.

Gildess Fe 1.5/30 Toxicity & Overdose Risk

The most toxic dose of oral contraceptives in mice is 6g/kg and the lowest toxic dose in women is 42mg/kg. No serious side effects have been reported in relation to an overdose of oral contraceptives, even when ingested by children. Overdosing on oral contraceptives could lead to nausea and vomiting.

image of a doctor in a lab doing drug, clinical research

Gildess Fe 1.5/30 Novel Uses: Which Conditions Have a Clinical Trial Featuring Gildess Fe 1.5/30?

160 active clinical trials are being conducted to determine the feasibility of Gildess Fe 1.5/30 in providing Birth Control, alleviating Atrophic Symptoms and increasing Low Testosterone levels.

Condition

Clinical Trials

Trial Phases

Birth Control

19 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Endometriosis

30 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Estrogen Deprivation Symptoms

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

female castration

0 Actively Recruiting

Atrophic

5 Actively Recruiting

Phase 4, Not Applicable

Hormone Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Fracture

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Menopause

0 Actively Recruiting

Gildess Fe 1.5/30 Reviews: What are patients saying about Gildess Fe 1.5/30?

4.7

Patient Review

9/2/2015

Gildess Fe 1.5/30 for Birth Control

I've been on this birth control for seven years. It's never failed to clear up my acne and prevent pregnancy (when taken as directed). I did stop taking it for a few years and still didn't get pregnant, so that's great!

4.3

Patient Review

12/29/2015

Gildess Fe 1.5/30 for Absence of Menstrual Periods

I've been using Gildess for four months now, and I've definitely noticed some changes. Most notably, my breasts and hips have gotten bigger, I've had more mood swings, and my period has stopped (two months). In terms of preventing pregnancy, though, this product is effective.

4

Patient Review

8/2/2016

Gildess Fe 1.5/30 for Birth Control

I've been pleased with how regular my period has become since starting this pill; however, the fever and muscle tightness I occasionally experience is really quite uncomfortable.

3.7

Patient Review

4/3/2016

Gildess Fe 1.5/30 for Birth Control

Gildess helped me with my endometriosis for the first 11 months, but then it came back worse than before. It also caused severe mood swings, paranoia, and anxiety. I don't recommend this medication to anyone.

3.3

Patient Review

10/7/2015

Gildess Fe 1.5/30 for Birth Control

Though I originally loved how light my periods became, I experienced severe emotional problems. this caused a lot of tension in my relationship which eventually led to my fiancé breaking up with me. After switching to Mirena, though, I feel like myself again.

3.3

Patient Review

12/28/2015

Gildess Fe 1.5/30 for Painful Periods

This medication helped with my period pain and flow, but unfortunately also caused me to experience severe depression. I would go from feeling sad to angry very quickly, taking out my frustrations on those around me.

2.3

Patient Review

1/17/2016

Gildess Fe 1.5/30 for Abnormally Long or Heavy Periods

I'm only on my first month of this pill, and I find that my emotions are all over the place. For example, I cried over something really insignificant the other day. My self-esteem is lower than it's ever been. I might switch to a different pill soon.

2

Patient Review

3/20/2016

Gildess Fe 1.5/30 for Endometriosis

I gave this medication a try for two months, but I found the side effects intolerable. Nausea for the first few days, then acne and severe mood swings. My usual upbeat attitude was replaced with depression and irrational crying. On top of that, I was spotting every day. So, all in all, not worth it for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gildess fe 1.5/30

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Microgestin?

"You may experience nausea, vomiting, headaches, bloating, breast tenderness, fluid retention in your ankles/feet, or weight changes. You may also experience vaginal bleeding between your periods (spotting) or miss/have irregular periods, especially during the first few months of using this medication."

Answered by AI

What is Cyclafem generic for?

"The active ingredients in Cyclafem 1/35 are norethindrone and ethinyl estradiol. This product is indicated for the prevention of pregnancy in women who elect to use it as a form of contraception."

Answered by AI

What is Gildess used to treat?

"This contraceptive medication consists of two hormones, norethindrone (a progestin) and ethinyl estradiol (an estrogen), and is effective in preventing pregnancy."

Answered by AI

What is Larin Fe generic for?

"Larin Fe is a combined oral contraceptive that contains the female hormones estrogen and progestogen, as well as an iron supplement. It is used to prevent pregnancy in women who choose oral contraceptives as their method of contraception. Larin Fe is available in generic form."

Answered by AI

Clinical Trials for Gildess Fe 1.5/30

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Gildess Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Gildess Fe 1.5/30, we think they might fit your search criteria.
Go to Trials
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Gildess Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Gildess Fe 1.5/30, we think they might fit your search criteria.
Go to Trials

Have you considered Gildess Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Gildess Fe 1.5/30, we think they might fit your search criteria.
Go to Trials